Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Catecholaminergic polymorphic ventricular tachycardia.

Johnson Francis1, Vikram Sankar, Venugopal Krishnan Nair

  • 1Department of Cardiology, Medical College Calicut, Kerala, India. pulikkottil2002@hotmail.com

Heart Rhythm
|April 21, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sedation Strategies, Drugs, and Protocols Used in Catheter Ablation of Atrial Fibrillation: A Focused Review.

Reviews in cardiovascular medicine·2026
Same author

J-Wave Syndromes: Reconciling the Complexity.

JACC. Clinical electrophysiology·2026
Same author

Inflammatory Hot Phases and Disease Trajectory in Desmosomal Cardiomyopathies.

Circulation·2026
Same author

Gene-based Therapies for Cardiovascular Medicine-Incorporating Molecular Medicine into Contemporary Cardiology.

The Canadian journal of cardiology·2026
Same author

Contemporary Perspectives on J-Wave Syndromes: An Expert Consensus Statement.

Journal of arrhythmia·2026
Same author

A novel computational model of human iPSC-derived ventricular myocytes with improved L-type calcium current for application to Timothy syndrome.

Scientific reports·2026

Catecholaminergic polymorphic ventricular tachycardia (VT) is a rare genetic heart condition causing dangerous arrhythmias. Current treatments like beta-blockers show limited efficacy, leading to increased use of defibrillators.

Area of Science:

  • Cardiology
  • Genetics
  • Pediatric Medicine

Background:

  • Catecholaminergic polymorphic ventricular tachycardia (VT) is a rare, inherited arrhythmogenic disorder.
  • It typically affects the pediatric age group, presenting with exercise- or stress-induced ventricular tachyarrhythmias, syncope, or sudden cardiac death.
  • Familial occurrence is noted in approximately 30% of cases, with autosomal dominant or recessive inheritance patterns.

Purpose of the Study:

  • To review the genetic basis and clinical characteristics of catecholaminergic polymorphic VT.
  • To discuss the current understanding of treatment efficacy and evolving management strategies.
  • To highlight the progressive nature and high mortality risk associated with untreated catecholaminergic polymorphic VT.

Main Methods:

Related Experiment Videos

  • Review of existing literature on catecholaminergic polymorphic VT.
  • Analysis of genetic mutations associated with the condition, including RyR2, CASQ2, and Ankyrin-B.
  • Evaluation of clinical presentation, diagnostic criteria, and treatment outcomes.

    • Main Results:

    • Mutations in RyR2 (autosomal dominant) and CASQ2 (recessive) are primary genetic causes.
    • Ankyrin-B mutations are also implicated, previously linked to long-QT 4.
    • Ventricular ectopy and polymorphic VT manifest progressively with increased heart rate.
    • Untreated cases have a 30-50% mortality risk before age 30.

    Conclusions:

    • Beta-blocker therapy demonstrates low efficacy in preventing recurrence and carries risks.
    • Due to treatment limitations and high sudden cardiac death risk, there is a growing trend towards implantable defibrillator implantation.
    • Early diagnosis and genetic counseling are crucial for managing this severe pediatric arrhythmia.